Noven Pharmaceuticals, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
9
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 10, 2027
- 1 fee due Sep 29, 2027The maintenance fee for Multi-polymer compositions for transdermal drug delivery (US 9,295,726) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol (US 9,314,470) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Amphetamine Carbamate Compounds and Methods (US 11,976,026) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,867,986 | Enhanced drug delivery in transdermal systems In force · From the USPTO record | In force | From the USPTO record | |
| US 8,815,281 | Transdermal drug delivery device including an occlusive backing In force · From the USPTO record | In force | From the USPTO record | |
| US 9,724,310 | Transdermal estrogen device and delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 9,730,900 | Transdermal estrogen device and delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 9,833,419 | Transdermal estrogen device and delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 7,989,496 | Transdermal delivery of ketoprofen polar derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 8,586,080 | Inhibiting crystallization of steroidal hormones in transdermal delivery systems In force · From the USPTO record | In force | From the USPTO record | |
| US 8,231,906 | Transdermal estrogen device and delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 8,852,628 | Transdermal drug delivery system for diclofenac In force · From the USPTO record | In force | From the USPTO record | |
| US 8,784,877 | Transdermal levonorgestrel device and delivery In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 32: 1 patent in force now held by others · 8 lapsed for an unpaid fee · 62 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 44 no status recorded